Re: Limit Use of Nasal Decongestant Sprays to Five Days, UK Regulator Says

Why It Matters

Limiting spray duration helps prevent rebound nasal congestion, reducing long‑term health costs and safeguarding consumer safety. The recommendation also signals tighter labeling and usage standards for OTC decongestants.

Key Takeaways

• MHRA limits xylometazoline, oxymetazoline sprays to five days
• Overuse can cause rhinitis medicamentosa, rebound congestion
• Recommendation echoes 2002 BMJ warning on spray rebound
• OTC nasal spray labels may require stricter usage warnings
• Clinicians should counsel patients on short‑term decongestant use

Pulse Analysis

The MHRA’s five‑day limit on xylometazoline and oxymetazoline nasal sprays reflects a broader regulatory trend toward tighter oversight of over‑the‑counter (OTC) medicines. While these topical decongestants provide rapid relief for acute nasal congestion, their vasoconstrictive action can quickly lead to a paradoxical swelling of the nasal mucosa—known as rhinitis medicamentosa—if used beyond a short window. By codifying a five‑day ceiling, the agency aligns UK practice with decades‑old clinical guidance and reinforces the principle that short‑term use is both safe and effective.

From a clinical perspective, the advisory underscores the importance of patient education at the point of sale. Pharmacists and primary‑care providers must now explicitly warn shoppers about the risk of rebound congestion and advise them to discontinue use after five days or switch to saline rinses. This proactive counseling can curb the progression to chronic nasal obstruction, which often necessitates prescription‑only therapies, specialist referrals, and increased healthcare expenditures. Moreover, the guidance may prompt a resurgence of interest in alternative, non‑pharmacologic treatments such as nasal irrigation and humidification.

The market implications are equally significant. Manufacturers of nasal decongestant sprays may need to redesign packaging to feature prominent five‑day usage warnings, potentially incurring additional compliance costs. Retailers could see a shift in consumer purchasing patterns, with a possible uptick in sales of adjunct products like saline sprays that are not subject to the same restrictions. Ultimately, the MHRA’s stance serves as a reminder that even well‑established OTC drugs require vigilant monitoring to protect public health while maintaining consumer confidence.